StreetInsider.com News Articles

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Tue, 21 Jul 2026 07:30:00 -0400

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.

Webcast and Conference Call Details

Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.

For analysts that

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Tue, 21 Jul 2026 07:30:00 -0400

PASADENA, Calif.--(BUSINESS WIRE)--

Webcast and Conference Call Details

For analysts that

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Tue, 21 Jul 2026 07:30:00 -0400

PASADENA, Calif.--(BUSINESS WIRE)--

Webcast and Conference Call Details

For analysts that

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Tue, 21 Jul 2026 07:30:00 -0400

PASADENA, Calif.--(BUSINESS WIRE)--

Webcast and Conference Call Details

For analysts that

Stifel Starts Arrowhead Pharma (ARWR) at Buy

Mon, 13 Jul 2026 16:07:31 -0400

(Updated - July 13, 2026 4:07 PM EDT)

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Buy rating and a price target of $98.00.

The analyst comments "We're initiating coverage of Arrowhead with a Buy and a $98 target price. Our thesis boils down to a view that: (1) SASHTA-3/4 [3Q] should establish plozasiran as a best-in-class drug; (2) we're optimistic on the size of the sHTG market where we model a ~$3B opportunity with potentially even conservative assumptions, which provides a meaningful floor for shares, even as the stock has re-rated; (3) while early and there

Stifel Starts Arrowhead Pharma (ARWR) at Buy

Mon, 13 Jul 2026 16:07:31 -0400

(Updated - July 13, 2026 4:07 PM EDT)

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Buy rating and a price target of $98.00.

Stifel Starts Arrowhead Pharma (ARWR) at Buy

Mon, 13 Jul 2026 16:07:31 -0400

(Updated - July 13, 2026 4:07 PM EDT)

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Buy rating and a price target of $98.00.

Stifel Starts Arrowhead Pharma (ARWR) at Buy

Mon, 13 Jul 2026 16:07:31 -0400

(Updated - July 13, 2026 4:07 PM EDT)

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Buy rating and a price target of $98.00.

H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Thu, 02 Jul 2026 06:43:05 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $100.00 price target on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented: "On June 29, Arrowhead hosted Part 1 of its Summer 2026 Cardiometabolic R&D Webinar, featuring Senior Vice President, Finance and Investor Relations Vince Anzalone, CFA, Chief Medical Officer and Head of R&D James Hamilton, M.D., MBA, Vice President of Clinical Development Jennifer Hellawell, M.D., and key opinion leader (KOL) Steven Nissen, M.D., Chief Academic Officer, Heart, Vascular and Thoracic Institute, at Cleveland Clinic (link to webinar and slides). The webinar reinforced that Arrowhead’s cardiometabolic franchise of small interfering RNA (siRNA)

EU approves Arrowhead's plozasiran for rare triglyceride disorder

Mon, 22 Jun 2026 12:36:33 -0400

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that the European Commission has granted marketing authorization for REDEMPLO (plozasiran) to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS), a rare disease characterized by extremely high triglyceride levels that can lead to acute pancreatitis and other serious complications.

The authorization covers patients diagnosed either by clinical criteria or genetic testing. The European Medicines Agency noted that while other authorized medicines exist for FCS confirmed by genetic testing, REDEMPLO does not require genetic confirmation, expanding the eligible patient population.

The approval is supported by data from the Phase 3 PALISADE study, a randomized, double-blind, placebo-controlled

EU approves Arrowhead's plozasiran for rare triglyceride disorder

Mon, 22 Jun 2026 12:36:33 -0400

The approval is supported by data from the Phase 3 PALISADE study, a randomized, double-blind, placebo-controlled

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Mon, 22 Jun 2026 12:33:00 -0400

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition
People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of life
Marketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo

PASADENA, Calif.--(BUSINESS WIRE)--